MELBOURNE, AUSTRALIA: Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell platform to treat cancer, announced that Dr Nicole van der Weerden has been appointed to the role of Chief Operating Officer, commencing 4 January 2023. Dr van der Weerden brings over 15 years of strong…